To became a global player in the Biotech market with a special focus in the phage therapy technology, with the ambition to be one of the first companies to reach the world market.
- To Launch 6 innovative biological products between 2024 and 2030, targeting the treatment of “unmet needs”, such as the “diabetic foot” that causes millions of amputations annually;
- Expected to launch the first product in third quarter of 2024 (TP-102 for diabetic foot treatment);
- Develop a new industrial GMP Biopharma unit in Portugal, for the production of biological medicines Lown Products and also able to provide CMO Production for third parties;
- Assume a reference position in the Portuguese market as an exporter of innovative biological pharmaceutical products.